A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Stopped early · Phase 1/Phase 2

Conditions studied: Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma

In brief

This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Key facts

Study ID

NCT04187404

Run by

Enterome

People needed

70

Starts

2020-07-23

Expected to finish

2024-10-02

Last updated by the study team

2026-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States
• Rigshospitalet — Copenhagen, Denmark
• Chu Lille — Lille, France
• Centre Léon Bérard — Lyon, France
• Assistance Publique - Hôpitaux de Marseille - Hôpital Nord — Marseille, France
• Institut Gustave Roussy — Villejuif, France
• Lmu Klinikum — München, Germany
• Universitätsklinikum Würzburg — Würzburg, Germany
• Azienda Ospedaliera Spedali Civili — Brescia, Italy
• Amsterdam UMC, location VUmc — Amsterdam, Netherlands
• Hospital Universitari Vall d'Hebron — Barcelona, Spain
• Karolinska University Hospital — Stockholm, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.